Alejandro Gomez-Pinillos

TL;DR: In this paper, dual PI3K/mTOR kinase inhibitors have been developed with the idea of overcoming resistance to the mTOR inhibition through preventing the activation of PI 3K/Akt as a result of release negative feedback loops.

TL;DR: The 40 mg panobinostat/bicalutamide regimen increased rPF survival in CRPC patients resistant to 2ndLAARx and merits validation using a second-generation antiandrogen.

TL;DR: Strategies to regain control of increased AR transcription may overcome resistance of AI‐cells and improve treatment outcomes.

TL;DR: Data suggest that decreased availability of functional KLF6 contributes to clinical PC progression and this decrease arises infrequently by somatic mutation and more commonly by the acquisition of SVs that provide a survival advantage under castrate conditions, enabling resistance to hormone therapy.

TL;DR: Oral, intermittent PAN in combination with daily Bic is well tolerated in CRPC pts progressing on second line hormones and shows promising PSA responses suggesting anti-AR activity.